Ascendis Pharma AS (NASDAQ:ASND) – Research analysts at Wedbush issued their Q3 2016 earnings per share estimates for Ascendis Pharma AS in a report issued on Monday. Wedbush analyst L. Moussatos anticipates that the firm will post earnings per share of ($0.66) for the quarter. Wedbush has a “Outperform” rating and a $34.00 price target on the stock. Wedbush also issued estimates for Ascendis Pharma AS’s Q4 2016 earnings at ($0.66) EPS, FY2016 earnings at ($2.83) EPS, FY2017 earnings at ($2.63) EPS, FY2018 earnings at ($3.11) EPS, FY2019 earnings at ($3.93) EPS and FY2020 earnings at ($2.71) EPS.
Several other research analysts also recently weighed in on ASND. Zacks Investment Research upgraded shares of Ascendis Pharma AS from a “sell” rating to a “hold” rating in a research report on Tuesday, July 26th. Leerink Swann reiterated a “buy” rating on shares of Ascendis Pharma AS in a research report on Friday, September 2nd. Finally, TheStreet upgraded shares of Ascendis Pharma AS from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th.
Shares of Ascendis Pharma AS (NASDAQ:ASND) opened at 20.66 on Wednesday. The firm has a 50-day moving average of $18.70 and a 200 day moving average of $16.10. Ascendis Pharma AS has a 1-year low of $11.92 and a 1-year high of $21.70. The company’s market capitalization is $520.49 million.
Ascendis Pharma AS (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.10.
About Ascendis Pharma AS
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma AS and related companies with MarketBeat.com's FREE daily email newsletter.